Skip to main content
. 2022 Oct 23;9(10):ofac485. doi: 10.1093/ofid/ofac485

Figure 1.

Figure 1.

Persistence of humoral (A) and cell-mediated (B) immune responses to RZV up to the second interim analysis of ZOE-LTFU (ATP cohort for persistence). aPrevaccination values from all RZV recipients in the humoral immunogenicity/CMI subsets in ZOE-50 and ZOE-70 [6]. Year 5 data for CD4[2+] T-cell frequencies are not shown because only 3 participants had available results for this analysis. bAt the data lock point for the second interim analysis in ZOE-LTFU, data collection for year 10 was still incomplete. Abbreviations: ATP, according-to-protocol; CI, confidence interval; CMI, cell-mediated immunity; gE, glycoprotein E; GMC, geometric mean concentration; CD4[2+] T cells, CD4+ T cells expressing at least 2 of 4 assessed activation markers (interferon-γ, interleukin-2, tumor necrosis factor–α, and CD40 ligand) per 106 CD4+ T cells; Q1 and Q3, first and third quartiles, respectively; mIU/mL, milli-International Units per milliliter; N, number of participants with available results; RZV, adjuvanted recombinant zoster vaccine; ZOE-LTFU, long-term follow-up study of ZOE-50/70.